Membranous Nephropathy Market Rapid Growth, Competition Outlook and Future Scope 2027


Posted July 5, 2021 by shriya

Membranous Nephropathy Market to expand at a meteoric CAGR of 3.5% by 2027, Global Membranous Nephropathy Market Size, Share, Growth, Trends and Industry Analysis by Type, Treatment, Diagnosis, End-Users

 
Membranous Nephropathy Market Research Report: Type (Primary, Secondary) Treatment (Conservative Therapy, Non-Immunosuppressive Therapy) Diagnosis (CT Scan, Urine Test, Blood Test) End User (Hospitals, Specialty Centers) – Global forecast till 2027

Market Highlights

Membranous nephropathy is a kidney disorder. It is an autoimmune disorder which can occur by itself or in conjunction with several other diseases. Membranous nephropathy is one of the most common causes of nephrotic syndrome. Membranous nephropathy can be caused due to various factors such as any autoimmune disease, use of certain medications such as nonsteroidal anti-inflammatory drugs, and exposure to certain infection such as hepatitis B, hepatitis C, and syphilis.

According to the World Health Organization (WHO), globally around 71 million people have the hepatitis C infection. This alarming rate of hepatitis C infections globally is likely to increase the market for membranous nephropathy.

The Global Membranous Nephropathy Market is expected to grow at a CAGR of 3.5% during the forecast period.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/5759

Regional Analysis

The Americas dominates the global membranous nephropathy market owing to the rising aging population and increasing rate of kidney disorders. Additionally, rising patient population rates along with increasing healthcare expenditure are likely to enhance the growth of membranous nephropathy in the North American region. Similarly, according to the National Kidney Foundation, in 2015 the U.S. is expected to spend around USD 48 million for the treatment of chronic kidney diseases.

Europe accounts for the second largest market due to increasing aging mass and increasing obesity rates. Additionally, improving government support and increasing healthcare infrastructure along with rising demand for technologically advanced treatment is driving the growth of the membranous nephropathy market in Europe. For instance, Eurostat estimated that over 19.2% of the population in Europe was aged 65 and above. Additionally, according to NHS, around 215,000 people have hepatitis C in the U.K. These rising rates in infection affected population is likely to drive the growth of the membranous nephropathy market.

Asia Pacific is the fastest growing market for membranous nephropathy whose growth is attributed to the rising population, which in turn increases the overall patient population and rising population affected by genetic disorders. Additionally, increasing healthcare expenditure and demand for new and innovative treatment options along with the rise in the standard of living are likely to drive the growth of the market. India and China are the foremost contributors to the market growth due to the growing demand for advanced treatments and rising rapid development of healthcare infrastructure in these regions.

On the other hand, the Middle East and Africa is expected to witness a limited growth due to limited access to healthcare and lack of awareness among individuals. In the Middle East, the growth of the market is driven by the increasing introduction of new and innovative products for diagnostic and treatment of various chronic diseases.

Segmentation

The global membranous nephropathy market is segmented on the basis of type, treatment, diagnosis, and end-user.

On the basis of type, the market is segmented into primary and secondary.

On the basis of treatment, the market is segmented into conservative therapy, non-immunosuppressive therapy, and immunosuppressive therapy.

On the basis of diagnosis, the market is segmented into urine test (urinalysis), blood test, glomerular filtration rate test, antinuclear antibody test, kidney ultrasound or Computed Tomography (CT), kidney biopsy, anti-PLA2R antibody test, and others.

On the basis of end-user, the market is segmented into research centers, hospitals, and specialty centers.

Key Players

Some of the key players in the Membranous Nephropathy market are Abbvie, Inc., Allergan Plc., Amgen Inc., AstraZeneca Plc, F. Hoffmann-La Roche Ltd, and FibroGen, Pfizer Inc., among others.

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/membranous-nephropathy-market-5759

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: [email protected]
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Akash Anand
Country United States
Categories Publishing , Research , Technology
Tags Membranous Nephropathy Market
Last Updated July 5, 2021